Houston-based symplr has acquired a Dallas SaaS company as it grows its software offerings to its health care clients. Image via symplr.com

A Houston-based health tech company is on an acquisition roll — it's latest deal marks the 11th acquisition in six years.

Software-as-a-service company symplr, which makes health care governance, risk management, and compliance software, has acquired Dallas-based data management SaaS company, Phynd Technologies. Symplr, which is backed by Clearlake Capital Group L.P. and SkyKnight Capital, did not disclose the terms of the transaction.

Symplr's burst of M&A activity spurs from the growing company's mission of providing end-to-end healthcare GRC portfolio, according to a news release. Phynd's platform manages data to provider profiles, locations, clinical expertise, availability, and health plan and network participation.

"Delivering new and significant ongoing value to our customers is integral to symplr's mission. Bringing Phynd into the symplr family helps us further deliver on that promise," says BJ Schaknowski, CEO of symplr, in the news release. "Phynd will integrate with our existing provider software solutions to create an end-to-end provider data management platform for hospitals, health systems, and payers that is unmatched in the healthcare industry today. We're excited to continue leading the healthcare GRC industry with innovative solutions that drive meaningful change."

Phynd was founded in 2012 and raised its $8 million series B in January 2019, according to Crunchbase.

"In the digital healthcare era, organizations must manage their providers and locations as searchable products that are accessible by consumers, referring providers and staff, and care delivery and revenue cycle teams. The combination of symplr and Phynd offers a unique, holistic provider data management offering that includes all providers, locations and virtual visits, helping healthcare organizations become more efficient and competitive," says Tom White, CEO of Phynd, in the release.

"symplr now offers the most robust and scalable central hub of continuously-curated credentialed and referring provider data. We are enthusiastic about executing as one organization and jointly expanding symplr's market leadership," he continues.

The Phynd acquisition is the sixth since symplr formed its partnership with private equity firms Clearlake and SkyKnight in 2018. Based in Santa Monica and Dallas, Clearlake is focused on software solutions across industries and currently has approximately $30 billion of assets under management. San Francisco-based SkyKnight Capital manages over $1.5 billion of PE capital and invests in healthcare, insurance, and business services.

Last year, symplr was named to Deloitte's 26th annual North America Technology Fast 500.The companies on the list were selected based on percentage fiscal year revenue growth from 2016 to 2019. The company came in at No. 426 on the national list with 221 percent growth.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston femtech co. debuts new lactation and wellness pods

mom pod

Houston-based femtech company Work&, previously known as Work&Mother, has introduced new products in recent months aimed at supporting working mothers and the overall health of all employees.

The company's new Lactation Pod and Hybrid Pod serve as dual-use lactation and wellness spaces to meet employer demand, the company shared in a news release. The compact pods offer flexible design options that can serve permanent offices and nearly all commercial spaces.

They feature a fully compliant lactation station while also offering wellness functionalities that can support meditation, mental health, telehealth and prayer. In line with Work&'s other spaces, the pods utilize the Work& scheduling platform, which prioritizes lactation bookings to help employers comply with the PUMP Act.

“This isn’t about perks,” Jules Lairson, Work& co-founder and COO, said in the release. “It’s about meeting people where they are—with dignity and intentional design. That includes the mother returning to work, the employee managing anxiety, and everyone in between.”

According to the company, several Fortune 500 companies are already using the pods, and Work& has plans to grow the products' reach.

Earlier this year, Work& introduced its first employee wellness space at MetroNational’s Memorial City Plazas, representing Work&'s shift to offer an array of holistic health and wellness solutions for landlords and tenants.

The company, founded in 2017 by Lairson and CEO Abbey Donnell, was initially focused on outfitting commercial buildings with lactation accommodations for working parents. While Work& still offers these services through its Work&Mother branch, the addition of its Work&Wellbeing arm allowed the company to also address the broader wellness needs of all employees.

The company rebranded as Work& earlier this year.

Rice biotech studio secures investment from Modi Ventures, adds founder to board

fresh funding

RBL LLC, which supports commercialization for ventures formed at the Rice University Biotech Launch Pad, has secured an investment from Houston-based Modi Ventures.

Additionally, RBL announced that it has named Sahir Ali, founder and general partner of Modi Ventures, to its board of directors.

Modi Ventures invests in biotech companies that are working to advance diagnostics, engineered therapeutics and AI-driven drug discovery. The firm has $134 million under management after closing an oversubscribed round this summer.

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. William McKeon, president and CEO of the TMC, previously called the launch of RBL a “critical step forward” for Houston’s life sciences ecosystem.

“RBL is dedicated to building companies focused on pioneering and intelligent bioelectronic therapeutics,” Ali said in a LinkedIn post. “This partnership strengthens the Houston biotech ecosystem and accelerates the transition of groundbreaking lab discoveries into impactful therapies.”

Ali will join board members like managing partner Paul Wotton, Rice bioengineering professor Omid Veiseh, scientist and partner at KdT Ventures Rima Chakrabarti, Rice alum John Jaggers, CEO of Arbor Biotechnologies Devyn Smith, and veteran executive in the life sciences sector James Watson.

Ali has led transformative work and built companies across AI, cloud computing and precision medicine. Ali also serves on the board of directors of the Drug Information Association, which helps to collaborate in drug, device and diagnostics developments.

“This investment by Modi Ventures will be instrumental to RBL’s growth as it reinforces confidence in our venture creation model and accelerates our ability to develop successful biotech startups,” Wotton said in the announcement. "Sahir’s addition to the board will also amplify this collaboration with Modi. His strategic counsel and deep understanding of field-defining technologies will be invaluable as we continue to grow and deliver on our mission.”